Tag | Content |
---|---|
UniProt Accession | MERL_HUMAN; P35240; |
Entrez ID | 4771 |
GenBank Protein ID | NM_000268.3; NM_016418.5; NM_181825.2; NM_181828.2; NM_181829.2; NM_181830.2; NM_181831.2; NM_181832.2; NM_181833.2; |
GenBank Nucleotide ID | NP_000259.1; NP_057502.2; NP_861546.1; NP_861966.1; NP_861967.1; NP_861968.1; NP_861969.1; NP_861970.1; NP_861971.1; |
Protein Name | Merlin (Moesin-ezrin-radixin-like protein) (Neurofibromin-2) (Schwannomerlin) (Schwannomin) |
Gene Name | NF2; SCH |
Organism | Homo sapiens |
NCBI Taxa ID | 9606 |
Functional Description | Probable regulator of the Hippo/SWH (Sav/Wts/Hpo) signaling pathway, a signaling pathway that plays a pivotal role in tumor suppression by restricting proliferation and promoting apoptosis. Along with WWC1 can synergistically induce the phosphorylation of LATS1 and LATS2 and can probably function in the regulation of the Hippo/SWH (Sav/Wts/Hpo) signaling pathway. May act as a membrane stabilizing protein. May inhibit PI3 kinase by binding to AGAP2 and impairing its stimulating activity. Suppresses cell proliferation and tumorigenesis by inhibiting the CUL4A-RBX1-DDB1-VprBP/DCAF1 E3 ubiquitin-protein ligase complex. |
Sequence (Fasta) | MAGAIASRMS FSSLKRKQPK TFTVRIVTMD AEMEFNCEMK WKGKDLFDLV CRTLGLRETW 60 FFGLQYTIKD TVAWLKMDKK VLDHDVSKEE PVTFHFLAKF YPENAEEELV QEITQHLFFL 120 QVKKQILDEK IYCPPEASVL LASYAVQAKY GDYDPSVHKR GFLAQEELLP KRVINLYQMT 180 PEMWEERITA WYAEHRGRAR DEAEMEYLKI AQDLEMYGVN YFAIRNKKGT ELLLGVDALG 240 LHIYDPENRL TPKISFPWNE IRNISYSDKE FTIKPLDKKI DVFKFNSSKL RVNKLILQLC 300 IGNHDLFMRR RKADSLEVQQ MKAQAREEKA RKQMERQRLA REKQMREEAE RTRDELERRL 360 LQMKEEATMA NEALMRSEET ADLLAEKAQI TEEEAKLLAQ KAAEAEQEMQ RIKATAIRTE 420 EEKRLMEQKV LEAEVLALKM AEESERRAKE ADQLKQDLQE AREAERRAKQ KLLEIATKPT 480 YPPMNPIPAP LPPDIPSFNL IGDSLSFDFK DTDMKRLSME IEKEKVEYME KSKHLQEQLN 540 ELKTEIEALK LKERETALDI LHNENSDRGG SSKHNTIKKL TLQSAKSRVA FFEEL 596 |
|
Database | Annotation |
---|---|
Cancer Gene Census | meningioma, acoustic neuroma, renal meningioma, acoustic neuroma neurofibromatosis type 2 |
CTD (Curated) (count: 8) (view all) | MESH:D002292
; Carcinoma, Renal Cell MESH:D008579 ; Meningioma MESH:C537443 ; Meningioma, familial MESH:D008654 ; Mesothelioma MESH:C562839 ; Mesothelioma, Malignant MESH:D016518 ; Neurofibromatosis 2 |
HGMD (count: 351) (view all) | CP045525; Neurofibromatosis 2; Complex rearrangements
CP045526; Neurofibromatosis 2; Complex rearrangements CP005301; Neurofibromatosis 2; Complex rearrangements CD077834; Neurofibromatosis 2; Small deletions CD066383; Neurofibromatosis 2; Small deletions CD004510; Neurofibromatosis 2; Small deletions |
GWASdb (count: 8) (view all) | rs6006220; Blood pressure, CVD RF and other traits (body mass index (BMI), waist:hip ratio, renin activity in plasma, aldosterone concentration in plasma, BNP levels in plasma, alcohol consumption); hypertension
rs2857641; Blood pressure (response to angiotensin-converting enzyme inhibitor); hypertension rs2527335; Amyotrophic lateral sclerosis (sporadic); amyotrophic lateral sclerosis rs2857648; Urinary metabolites; kidney disease rs16987928; Urinary metabolites; kidney disease rs2530678; Blood pressure, CVD RF and other traits (body mass index (BMI), waist:hip ratio, renin activity in plasma, aldosterone concentration in plasma, BNP levels in plasma, alcohol consumption); hypertension |
PTM | Modification Sites |
---|---|
Phosphorylation (count: 15) (view all) | 10 GAIASRMSFSSLKRK dbPAF
12 IASRMSFSSLKRKQP dbPAF 13 ASRMSFSSLKRKQPK dbPAF 177 PKRVINLYQMTPEMW dbPAF 180 VINLYQMTPEMWEER dbPAF 189 EMWEERITAWYAEHR dbPAF |
Acetylation (count: 1) | 279 TIKPLDKKIDVFKFN PLMD |
Ubiquitination (count: 15) (view all) | 159 DYDPSVHKRGFLAQE PLMD
171 AQEELLPKRVINLYQ PLMD 253 PENRLTPKISFPWNE PLMD 269 RNISYSDKEFTIKPL PLMD 322 SLEVQQMKAQAREEK PLMD 364 ERRLLQMKEEATMAN PLMD |
Sumoylation (count: 2) | 550 KTEIEALKLKERETA PLMD
76 KDTVAWLKMDKKVLD PLMD |
Network | Interaction | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
A | B | Source | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|